Logo CICANCER
Intranet Colaborate

Old CIC Events

An evolutionary journey across the CLL course 25/06/2026

An evolutionary journey across the CLL course

Ferran Nadeu — Fundació Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

Defensa de tesis doctoral: Potenciación farmacológica de la involución postlactancia como estrategia de quimioprevención frente al cáncer de mama 19/06/2026

Defensa de tesis doctoral: Potenciación farmacológica de la involución postlactancia como estrategia de quimioprevención frente al cáncer de mama

Manuel Jesús Pérez Baena — Programa de doctorado de Biología y Clínica del Cáncer

Defensa de tesis: Análisis funcional de la E3 ligasa RNF212B durante la meiosis en ratón 19/06/2026

Defensa de tesis: Análisis funcional de la E3 ligasa RNF212B durante la meiosis en ratón

Raquel Sainz Urruela — Programa de Biología y Clínica del Cáncer

In search of the ideal Trojan horse for antitumor treatments 09/06/2026

In search of the ideal Trojan horse for antitumor treatments

Pilar Martín-Duque — Instituto de Salud Carlos lll, Departamento de Desarrollo de Medicamentos y Terapias Avanzadas (DDMTAs)

The therapeutic targeting of epitranscriptome-associated proteins 04/06/2026

The therapeutic targeting of epitranscriptome-associated proteins

Konstantinos Tzelepis — Cambridge Stem Cell Institute, University of Cambridge

Metabolic crosstalk between the tumour and the host 28/05/2026

Metabolic crosstalk between the tumour and the host

Karen Vousden — Francis Crick Institute, UK

Role of the repressor Capicua in KRAS-driven lung tumor development. 14/05/2026

Role of the repressor Capicua in KRAS-driven lung tumor development.

Irene Ballesteros González — Centro de Investigación del Cáncer (CSIC, USAL, FICUS)

Drug-mediated kinase activation: A new type of chemotherapy to target therapy-resistant cancer cells 07/05/2026

Drug-mediated kinase activation: A new type of chemotherapy to target therapy-resistant cancer cells

Óscar Fernández-Capetillo — CNIO-Instituto Karolinska, Sweden

A portfolio of immunotherapies to treat ALK+ cancers 30/04/2026

A portfolio of immunotherapies to treat ALK+ cancers

Roberto Chiarle — Department of Pathology (Boston Children's Hospital)

Evaluating Next-Generation CAR-T Cells in Complex Tumor-Immune Models 28/04/2026

Evaluating Next-Generation CAR-T Cells in Complex Tumor-Immune Models

Naiara Martínez-Vélez — Stanford University

Defensa de tesis doctoral: C3G in chronic myeloid leukemia: linking disease progression in mouse models with cellular leukemogenic mechanisms 17/04/2026

Defensa de tesis doctoral: C3G in chronic myeloid leukemia: linking disease progression in mouse models with cellular leukemogenic mechanisms

Pablo Berrocal — Programa de Doctorado: Biología y Clínica del Cáncer

ZMYM3 and ZNF292 mutations in chronic lymphocytic leukemia: clinical and biological implications 16/04/2026

ZMYM3 and ZNF292 mutations in chronic lymphocytic leukemia: clinical and biological implications

Alberto Rodríguez Sánchez — Centro de Investigación del Cáncer (CSIC-Universidad de Salamanca)